Flavonoids as efficient scaffolds: Recent trends for malaria, leishmaniasis, Chagas disease, and dengue

• Published in: Phytotherapy research 2019-10, Vol.33 (10), p.2473-2517
• Main Authors: Boniface, Pone Kamdem, Ferreira, Elizabeth Igne
• Format: Article
• Language: English
• Subjects: Antimalarial agents; Antiviral agents; Bioavailability; Chagas disease; Chagas Disease - drug therapy; dengue; Dengue - drug therapy; Dengue fever; Drug development; Drug resistance; Fatalities; Flavonoids; Flavonoids - therapeutic use; Humans; leads for molecular modification; Leishmaniasis; Leishmaniasis - drug therapy; Malaria; Malaria - drug therapy; Medical treatment; Molecular modelling; Neglected Diseases - drug therapy; Parasitic diseases; Pharmacokinetics; Pharmacology; Therapeutic applications; Toxicity; Tropical diseases; Vector-borne diseases; Viral diseases
• ISSN: 0951-418X; 1099-1573
• DOI: 10.1002/ptr.6383

Endemic in 149 tropical and subtropical countries, neglected tropical diseases (NTDs) affect more than 1 billion people annually with over 500,000 deaths. Among the NTDs, some of the most severe consist of leishmaniasis, Chagas disease, and dengue. The impact of the combined NTDs closely rivals that of malaria. According to the World Health Organization, 216 million cases of malaria were reported in 2016 with 445,000 deaths. Current treatment options are associated with various limitations including widespread drug resistance, severe adverse effects, lengthy treatment duration, unfavorable toxicity profiles, and complicated drug administration procedures. Flavonoids are a class of compounds that has been the subject of considerable scientific interest. New developments of flavonoids have made promising advances for the potential treatment of malaria, leishmaniasis, Chagas disease, and dengue, with less toxicity, high efficacy, and improved bioavailability. This review summarizes the current standings of the use of flavonoids to treat malaria and neglected diseases such as leishmaniasis, Chagas disease, and dengue. Natural and synthetic flavonoids are leading compounds that can be used for developing antiprotozoal and antiviral agents. However, detailed studies on toxicity, pharmacokinetics, and mechanisms of action of these compounds are required to confirm the in vitro pharmacological claims of flavonoids for pharmaceutical applications. Highlights In the current review, we have tried to compile recent discoveries on natural and synthetic flavonoids as well as their implication in the treatment of malaria, leishmaniasis, Chagas disease, and dengue. A total of 373 (220 natural and 153 synthetic) flavonoids have been evaluated for antimalarial, antileishmanial, antichagasic, and antidengue activities. Most of these flavonoids showed promising results against the above diseases. Reports on molecular modeling of flavonoid compounds to the disease target indicated encouraging results. Flavonoids can be prospected as potential leads for drug development; however, more rigorously designed studies on toxicity and pharmacokinetics, as well as the quantitative structure–activity relationship studies of these compounds, need to be addressed.